Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 1;8(1):608-14.
eCollection 2015.

Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence

Kai Zhang  1 , Hao Chen  1 , Bin Zhang  1 , Jiajia Sun  1 , Jian Lu  1 , Kangwu Chen  1 , Huilin Yang  1
Affiliations

Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence

Kai Zhang et al. Int J Clin Exp Pathol. .

Abstract

Chordoma is a rare and low-malignant neoplasm which is considered to arise from notochord remnants. Due to its large resistance to chemotherapy and radiotherapy, surgical resection so far is the prior treatment for chordoma. However, the recurrence rate is high even after complete surgical resection. Recently, targeted cancer therapy has been demonstrated to be effective in several other tumors, while the related research on chordoma is rare. Mitogen-activated protein kinase signaling pathway is acknowledged to participate in tumor development, in which Raf-1 and extracellular regulated protein kinase 1/2 (ERK1/2) play vital roles. In this study, we evaluated the expression of Raf-1 and ERK1/2 by immunohistochemical staining in 42 chordoma tissue and 16 distant normal tissue. Moreover, we also investigated the correlations of Raf-1 and ERK1/2 expression with clinical features in sacral chordoma. Expression of Raf-1 and ERK1/2 was both significantly higher in sacral chordoma tissue than distant normal tissue (P = 0.008, P = 0.019). Raf-1 positive expression was related to surrounding muscle invasion (P = 0.032) and chordoma recurrence (P = 0.002), but the results did not indicate any association with patients' age, gender, tumor size and location. ERK1/2 was associated with tumor size (P = 0.044) instead of other clinical factors (P > 0.05). Spearman correlation test showed close relation between ERK1/2 and Raf-1 (P = 0.001, r = 0.518). Kaplan-Meier survival Curve and log-rank test showed that Raf-1 positive expression was associated with shorter continuous disease-free survival time (CDFS) (P = 0.001), while ERK1/2 had no relation to CDFS (P = 0.961). Conclusively, Raf-1 may be an important biomarker in predicting the prognosis of chordoma patients.

Keywords: ERK1/2; Raf-1; prognosis; recurrence; sacral chordoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Negative expression of Raf-1 in sacral chordoma. B. Positive expression of Raf-1 in sacral chordoma. C. Negative expression of ERK1/2 in sacral chordoma. D. Positive expression of ERK1/2 in sacral chordoma (magnification, ×400).
Figure 2
Figure 2
Continuous disease-free survival according to the expression of Raf-1 in sacral chordoma.
Figure 3
Figure 3
Continuous disease-free survival according to the expression of ERK1/2 in sacral chordoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF, Flanagan AM. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572–580. - PubMed
    1. Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M, Serra M, Bruderlein S, Westhoff B, Melzner I, Bassaly B, Herms J, Hugo HH, Schulte M, Moller P. Molecular profiling of chordoma. Int J Oncol. 2014;44:1041–1055. - PMC - PubMed
    1. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12:1344–1350. - PubMed
    1. Li X, Ji Z, Ma Y, Qiu X, Fan Q, Ma B. Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. Oncol Lett. 2012;3:1268–1274. - PMC - PubMed
    1. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. Eur J Surg Oncol. 2014;40:1412–1420. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources